Literature DB >> 16216036

Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining.

Elisabeth Mangold1, Constanze Pagenstecher, Waltraut Friedl, Hans-Peter Fischer, Sabine Merkelbach-Bruse, Maike Ohlendorf, Nicolaus Friedrichs, Stefan Aretz, Reinhard Buettner, Peter Propping, Micaela Mathiak.   

Abstract

Microsatellite analysis (MSA) in tumour tissue is useful for pre-selection of hereditary non-polyposis colorectal cancer (HNPCC) patients for mutation screening, but is time-consuming and cost-intensive. Immunohistochemistry (IHC) for expression of MLH1 and MSH2 proteins is simple, fast, and indicates the affected gene. IHC has therefore been proposed as an alternative pre-screening method. However, some authors report a lower sensitivity of IHC compared with MSA. The present study reports IHC results for MSH2 and MLH1 performed in 82 tumours with high microsatellite instability (MSI-H) from 81 carriers of pathogenic mutations in MSH2 or MLH1. One hundred per cent (38/38) of the tumours from MSH2 mutation carriers showed loss of MSH2 staining; in all cases, the affected MSH2 gene was predicted correctly by IHC. Complete loss of MLH1 expression was observed in 66% (29/44) of MLH1 mutation carriers. Weak positive MLH1 staining was observed in 14 (32%) cases and, in one case, normal MLH1 staining was seen. The pathologist was aware of the weak staining pattern as an indicator of an MLH1 mutation; 98% of the MLH1 mutations were predicted correctly. To evaluate whether weak positive MLH1 staining is observed more often with in-frame or missense mutations, IHC data from 23 MSI-H tumours from carriers of unspecified variants were added and mutations were grouped into truncating mutations, large non-truncating deletions, and small non-truncating mutations. Weak MLH1 staining was observed in all three categories and it is postulated that other factors, such as mutation of the second allele, also influence protein expression. In conclusion, IHC can be regarded as a very useful method for selecting HNPCC patients for mutation analysis, as long as it is interpreted by an experienced pathologist. The high specificity of IHC in terms of indicating the affected gene is useful for evaluating unspecified variants. However, the staining pattern does not predict whether the underlying germ-line mutation is truncating or not. Copyright 2005 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216036     DOI: 10.1002/path.1858

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  34 in total

1.  Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.

Authors:  R C Niessen; M J W Berends; Y Wu; R H Sijmons; H Hollema; M J L Ligtenberg; H E K de Walle; E G E de Vries; A Karrenbeld; C H C M Buys; A G J van der Zee; R M W Hofstra; J H Kleibeuker
Journal:  Gut       Date:  2006-04-24       Impact factor: 23.059

Review 2.  Lynch syndrome diagnostics: decision-making process for germ-line testing.

Authors:  E Lastra; M García-González; B Llorente; C Bernuy; M J Barrio; L Pérez-Cabornero; M Durán; C García-Girón
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

3.  Introducing new health interventions: diagnostics is the Cinderella of health technology assessment.

Authors:  Peter N Furness
Journal:  BMJ       Date:  2006-01-28

4.  Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals.

Authors:  Mev Dominguez Valentin; Felipe Carneiro da Silva; Erika Maria Monteiro dos Santos; Bianca Garcia Lisboa; Ligia Petrolini de Oliveira; Fabio de Oliveira Ferreira; Israel Gomy; Wilson Toshihiko Nakagawa; Samuel Aguiar Junior; Mariana Redal; Carlos Vaccaro; Adriana Della Valle; Carlos Sarroca; Dirce Maria Carraro; Benedito Mauro Rossi
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

Review 5.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

6.  Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?

Authors:  Jennifer B Goldstein; William Wu; Ester Borras; Gita Masand; Amanda Cuddy; Maureen E Mork; Sarah A Bannon; Patrick M Lynch; Miguel Rodriguez-Bigas; Melissa W Taggart; Ji Wu; Paul Scheet; Scott Kopetz; Y Nancy You; Eduardo Vilar
Journal:  Clin Cancer Res       Date:  2017-05-18       Impact factor: 12.531

7.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Authors:  Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

8.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns.

Authors:  Iolanda Borelli; Guido C Casalis Cavalchini; Serena Del Peschio; Monica Micheletti; Tiziana Venesio; Ivana Sarotto; Anna Allavena; Luisa Delsedime; Marco A Barberis; Giorgia Mandrile; Paola Berchialla; Paola Ogliara; Cecilia Bracco; Barbara Pasini
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

10.  Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.

Authors:  Hellen Houlleberghs; Marleen Dekker; Hildo Lantermans; Roos Kleinendorst; Hendrikus Jan Dubbink; Robert M W Hofstra; Senno Verhoef; Hein Te Riele
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.